Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, ...
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...
Science Daily16h
Combination approach shows promise for treating rare, aggressive cancers
A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...
Clinical trial shows immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma
Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...
Science Daily21h
'Moonlighting' enzymes can lead to new cancer therapies
Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...